SCYX - SCYNEXIS Inc Stock Price, Fair Value and News

2.11USD+0.02 (+0.96%)Market Closed

Market Summary

USD2.11+0.02

Market Closed

0.96%

SCYX Stock Price

View Fullscreen

SCYX RSI Chart

SCYX Valuation

Market Cap

79.7M

Price/Earnings (Trailing)

0.79

Price/Sales (Trailing)

0.58

EV/EBITDA

0.42

Price/Free Cashflow

1.06

SCYX Price/Sales (Trailing)

SCYX Profitability

Operating Margin

89.50%

EBT Margin

72.80%

Return on Equity

136.74%

Return on Assets

85.69%

Free Cashflow Yield

94.18%

SCYX Fundamentals

SCYX Revenue

Revenue (TTM)

140.1M

Rev. Growth (Yr)

282.01%

Rev. Growth (Qtr)

229.38%

SCYX Earnings

Earnings (TTM)

101.3M

Earnings Growth (Yr)

101.21%

Earnings Growth (Qtr)

102.1%

Breaking Down SCYX Revenue

Last 7 days

-0.9%

Last 30 days

5.0%

Last 90 days

37.0%

Trailing 12 Months

-24.9%

How does SCYX drawdown profile look like?

SCYX Financial Health

Current Ratio

3.72

SCYX Investor Care

Shares Dilution (1Y)

3.46%

Diluted EPS (TTM)

2.08

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	38.9M	72.6M	106.4M	140.1M
2022	1.8M	3.1M	4.2M	5.1M
2021	5.5M	8.0M	10.6M	13.2M
2020	673.0K	476.0K	311.0K	2.9M
2019	394.5K	532.0K	669.5K	807.0K
2018	483.5K	672.5K	823.5K	257.0K
2017	221.0K	264.0K	325.0K	385.5K
2016	220.0K	195.0K	179.0K	180.0K
2015	1.3M	1.3M	1.3M	257.0K
2014	0	0	0	1.3M
2013	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of various fungal infections, including invasive candidiasis, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

CEO	Mr. David Gonzalez Angulo M.D.
WEBSITE	scynexis.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	36

SCYNEXIS Inc Frequently Asked Questions

What is the ticker symbol for SCYNEXIS Inc? What does SCYX stand for in stocks?

SCYX is the stock ticker symbol of SCYNEXIS Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of SCYNEXIS Inc (SCYX)?

As of Fri Jul 26 2024, market cap of SCYNEXIS Inc is 79.72 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SCYX stock?

You can check SCYX's fair value in chart for subscribers.

Is SCYNEXIS Inc a good stock to buy?

The fair value guage provides a quick view whether SCYX is over valued or under valued. Whether SCYNEXIS Inc is cheap or expensive depends on the assumptions which impact SCYNEXIS Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SCYX.

What is SCYNEXIS Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, SCYX's PE ratio (Price to Earnings) is 0.79 and Price to Sales (PS) ratio is 0.58. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SCYX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on SCYNEXIS Inc's stock?

In the past 10 years, SCYNEXIS Inc has provided -0.298 (multiply by 100 for percentage) rate of return.